Lexeo TherapeuticsLexeo Therapeutics
LT

Lexeo Therapeutics

Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases.

Website
2020Active91
Rate
Advertise here

About

Lexeo Therapeutics is a New York City-based, clinical-stage genetic medicine company focused on developing AAV-mediated treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease. The company leverages pioneering science and a stepwise development approach to advance its pipeline of therapeutic candidates, aiming to address significant unmet medical needs.

Technology stack

detected 2026-06-19
Est. monthly stack spend~$920/mo
EmailMicrosoft 365
Hosting
self_managed
Stack
jQueryWordPress
Analytics
Google Tag Manager
SEO
Yoast SEO
Maps
Google Maps
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Lexeo Therapeutics do?

Lexeo Therapeutics is a New York City-based, clinical-stage genetic medicine company focused on developing AAV-mediated treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease. The company leverages pioneering science and a stepwise development approach to advance its pipeline of therapeutic candidates, aiming to address significant unmet medical needs.

How much funding has Lexeo Therapeutics raised?

Lexeo Therapeutics has raised a total of $495M in funding. The most recent round on record is Public Offering.

Where is Lexeo Therapeutics headquartered?

Lexeo Therapeutics is headquartered in New York City, United States.

When was Lexeo Therapeutics founded?

Lexeo Therapeutics was founded in 2020.

What industry does Lexeo Therapeutics operate in?

Lexeo Therapeutics operates in Biotech, MedTech, HealthTech, Genomics, Drug Discovery, Clinical Trials.

How many employees does Lexeo Therapeutics have?

Lexeo Therapeutics has approximately 91 people on record.